European Expansion Inspire Medical Systems is actively expanding its European footprint, with reports of growing offices and over 80 employees supporting NHS adoption in England. This indicates increased regional needs for training, installation support, clinical education, and local regulatory/commercial partnerships that sales can target.

Revenue Momentum Recent results show revenue around $269 million and growth above expectations, signaling a favorable buying cycle for hospitals and clinics considering neurostimulation solutions for sleep apnea. This momentum can be leveraged to pursue larger hospital systems and integrated procurement deals.

Competitive Position Competitors such as Alphatec Spine and LivaNova are identified in the market, highlighting opportunities to differentiate Inspire’s FDA-approved implanted neurostimulation therapy. Sales approaches can emphasize regulatory standing, patient outcomes, and long-term service agreements to win contracts against rivals.

Key Stakeholders A recent CFO appointment and ongoing governance considerations present entry points to engage finance and procurement teams for budgeting, cost-of-ownership analyses, and favorable payment terms. Aligning value demonstrations with finance leadership can accelerate approvals for multi-site deployments.

Market Readiness With substantial patient unmet need in obstructive sleep apnea and NHS adoption growth in Europe, there is a clear market readiness for expanded therapy adoption. Target healthcare systems and surgeons with clinical outcomes data, payer considerations, and scalable support to drive broader implementation.